The “CRISPR Based Therapeutics Market by Type of Therapy, Therapeutic Approach, Therapeutic Area, and Key Geographical Regions: Industry Trends and Global Forecasts 2021-2030” report has been added to ResearchAndMarkets.com’s offering.
The report features a study of the current market landscape and future opportunity for the players involved in the development of CRISPR based therapeutics for the treatment of a variety of disease conditions. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies.
Clinical trials of CRISPR based therapeutics are currently focused mainly on oncological and haematological disorders; however, several product candidates against certain neurological disorders and infectious diseases, specifically targeting recurrent conditions, are under investigation. Post 2014, the overall interest in this technology has grown exponentially, with several start-ups entering the market and six of the top ten pharmaceutical companies restructuring their efforts in this direction.
Substantial body of evidence has also been generated validating the therapeutic applications of this technology, which has prompted many strategic partnerships (focused on therapy development and clinical research) and investment in innovator companies.
In fact, the three leading companies in this industry segment together have combined market capitalisation of more than $10 billion, and have raised more than $2.8 billion in various funding rounds. Despite the possibly limitless potential of the CRISPR/Cas technology, further investigation, probing its safety and therapeutic efficacy in large diverse populations, is required.
The report highlights key impediments to approval and other existing challenges that are being addressed by stakeholders, include off-target toxicity-related concerns and complexities related to the delivery of CRISPR components into target cells. Concerning delivery, innovators in this field have reported notable success using different types of platforms for facilitating the intracellular administration of CRISPR components; examples of successful delivery methods include electroporation, AAV vectors and lipid nanoparticles (LNPs).
It notes that A few companies are also evaluating bacteriophages as a potential delivery system for such products. Promising clinical results, and ongoing technical developments, coupled to the growing interest of biopharmaceutical developers, are anticipated to push pipeline products to higher phases and on to commercialisation. We believe that the market is likely to evolve at a commendable pace over the next decade.
